Residual symptoms in depression: an emerging therapeutic target.
about
Treatment of recurrent depressionIs remission of depressive symptoms in primary care a realistic goal? A meta-analysisFluoxetine versus placebo in preventing relapse of major depression in children and adolescents.Cognitive and affective trait and state factors influencing the long-term symptom course in remitted depressed patients.Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression.Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in YouthTelomere shortening in leukocyte subpopulations in depression.Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.Disability in late-life major depression: patterns of self-reported task abilities, task habits, and observed task performanceEnhancing the efficacy of antidepressants with psychotherapy.Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorderCognitive Therapy to Prevent Depressive Relapse in Adults.Psychosocial determinants of recovery in depression.Towards achieving remission in the treatment of depression.Preschool depression: homotypic continuity and course over 24 months.Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.Brain-immune interactions and disease susceptibility.Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.Are Improvements in Cognitive Content and Depressive Symptoms Correlates or Mediators during Acute-Phase Cognitive Therapy for Recurrent Major Depressive Disorder?Continuation-phase cognitive therapy's effects on remission and recovery from depression.Depressed Adolescents Treated with Exercise (DATE): A pilot randomized controlled trial to test feasibility and establish preliminary effect sizes.Approaches to understanding and addressing treatment-resistant depression: a scoping reviewProcognitive properties of drugs with single and multitargeting H3 receptor antagonist activities.Predictors of antidepressant response: A selective review.Two-year follow-up of a randomized controlled trial of stepped care cognitive behavioral therapy to prevent recurrence of depression in an older population.Are depressive residual symptoms independent of treatments?Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.Acute and chronic stress exposure predicts 1-year recurrence in adult outpatients with residual depression symptoms following response to treatment.Modelling of serotonin reuptake inhibitory and histamine H₃antagonistic activity of piperazine and diazepane amides: QSAR rationales for co-optimization of the activity profiles.Inter-episode mood lability in mood disorders: residual symptom or natural course of illness?Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?
P2860
Q22305946-B9313735-3978-4343-89E3-9C2C05AAC4F4Q24794437-27180AA1-7DC9-47B5-B692-D14407FF31ABQ33667966-41382B89-3A7D-425B-B226-35042631AEA5Q33757799-4EE5ADB9-0E0B-4BE2-8E62-6DF255D6811AQ33857182-E5B0C28F-A4D2-4AF9-B818-B6F17EB2A03CQ33900246-97E368BB-E267-496D-884E-2B81F472A092Q33902673-C197AF0B-9ABE-44ED-9F08-0428F05E670DQ33973909-AF769806-041A-4902-A337-B88EC9564888Q34036852-1F5B3D7F-57C1-4387-8A83-8B9BC04B56BBQ34518689-74256642-50E4-48DF-9245-EAA48520EA1BQ34694131-2A018CEB-0CDC-4242-9910-6F2DB5217193Q35115733-7D322594-FC9D-4E11-B7BE-078464A54C03Q35237027-BEC22CB3-A828-4252-B8F4-F232C3CE380FQ35237032-8CDB009F-DE6E-4269-80A4-A0B6DDC60E4FQ35250071-947D725D-131E-4606-958E-014A17116C85Q35626207-3A9C63C8-3BC4-4D3C-BA96-06355481CC6CQ36026815-18B48F5D-9A7F-4993-989C-94B7D82EAC1AQ36070303-83FF1518-CD33-4E60-9E24-9AAEBEF4C20FQ36078836-458E395F-47C4-4F2D-8CA3-56486B777315Q37202637-139A7E18-DF2F-46B9-81E7-196CA3A80768Q37307978-A8F88BB5-653C-4437-B744-7C343FF712FEQ38008653-DD2A5931-69B5-4AC2-960B-2419D15B4FFDQ38212433-2181A0A0-C535-4253-8145-35DDCD4BBFAFQ38220016-5FDB3411-9E9A-4DB6-8DD7-48FA96504CE5Q45350210-D4538D6D-BB82-4C86-A781-6014AE218DDBQ45772807-49EF0DFA-85A3-46D4-B723-448E9F312ED4Q46002104-D559A3BB-0841-43A6-9808-AD1C18F90074Q48425543-5B905A25-EB84-49F5-B889-F6A3F394E455Q48867382-A31E06AD-E269-4DB5-9CE9-145388A69854Q50989740-56D615B2-F5E7-4C48-94A1-71A55D1423AAQ55001644-2F2B106A-4833-421C-893A-CB5733AC7845
P2860
Residual symptoms in depression: an emerging therapeutic target.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Residual symptoms in depression: an emerging therapeutic target.
@ast
Residual symptoms in depression: an emerging therapeutic target.
@en
type
label
Residual symptoms in depression: an emerging therapeutic target.
@ast
Residual symptoms in depression: an emerging therapeutic target.
@en
prefLabel
Residual symptoms in depression: an emerging therapeutic target.
@ast
Residual symptoms in depression: an emerging therapeutic target.
@en
P1476
Residual symptoms in depression: an emerging therapeutic target.
@en
P2093
Giovanni Andrea Fava
Stefania Fabbri
P304
P356
10.1016/S0278-5846(02)00226-9
P577
2002-10-01T00:00:00Z